Across TCGA pan-cancer cohorts, TNFSF13B mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of TNFSF13B’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where TNFSF13B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TNFSF13B is over-expressed in tumor.
LUAD and CCRCC are the cancer types where TNFSF13B tumor–normal differential expression is most reproducible.